As Novo Nordisk hauls in huge sales from its popular GLP-1 products, the company is thinking about a future beyond obesity ...
Re­pub­li­cans and De­moc­rats on the Sen­ate Ju­di­cia­ry Com­mit­tee on Tues­day both ac­knowl­edged the need for fur­ther ...
AstraZeneca said it will continue to be the conduit for sharing Chinese innovation with the rest of the world, but will ...
The digital health company Hims & Hers has started prescribing a cheaper, compounded version of a popular GLP-1 weight loss ...
Sen­ate Fi­nance Chair Ron Wyden is press­ing Pfiz­er over its tax prac­tices as part of his in­ves­ti­ga­tion in­to how ...
Investors continue to flock toward antibody-drug conjugates. Pheon Therapeutics is the latest to catch the tailwinds of the ...
Larimar Therapeutics’ stock $LRMR shot up by as much as 20% after announcing Monday that the FDA had lifted its partial ...
AstraZeneca on Monday morning unveiled its ambitious plan to be one of the fastest growing pharma companies by the end of the ...
GSK announced Tuesday morning that its experimental antibody treatment reduced the yearly rate of asthma attacks across two ...
CAM­BRIDGE, UK — Pas­cal So­ri­ot has set an am­bi­tious $80 bil­lion rev­enue tar­get for As­traZeneca by 2030. But he’s not ...
Plus, news about BioNTech, Medigene, YGION Biomedical, Eli Lilly and Alloy Therapeutics: Lyra lays off 87 employees: The Watertown, MA-based biotech will let go of 75% of its workforce, stop ...
French phar­ma­ceu­ti­cal gi­ant Sanofi will work with the tech pow­er­house Ope­nAI and New York-based start­up For­ma­tion ...